Immunotherapy and chemo for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of a cancer immunotherapy (zimberelimab) and three chemotherapy drugs (SIRIOX) as a second-line treatment for people whose pancreatic cancer has stopped responding to the AG regimen. The goal is to see if this new mix can shrink tumors or slow progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your pancreatic cancer has gotten worse after treatment with the AG regimen (gemcitabine and nab-paclitaxel).
- You have never been treated with oxaliplatin, S-1, irinotecan, or an immunotherapy drug like a PD-1 inhibitor.
- You have at least one tumor that can be measured on a CT or MRI scan.
- Your day-to-day activity level is good (ECOG score 0 or 1).
- You do not have an active autoimmune disease or a history of one (except for conditions like vitiligo or childhood asthma that resolved).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests combining a type of precision radiation (SBRT) with an immunotherapy drug (zimberelimab) for patients with locally advanced pancreatic cancer that cannot be removed by surgery. It aims to see if this combination helps shrink the tumor or control the cancer better.
Hear when a new Previously AG Chemotherapy Treated Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.